Curis Inc.

CRIS

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001108205


None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $20.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data not computable: distress, fortress balance sheet
Inputs computable	6 of 13
Graded from	filings received through Mar 24, 2026 241 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$0.46 2026-11-19; market equity $4.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 24, 2026

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 98.5						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	64.1%	(6.7%)	98.5	756	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 97.2						
Altman Z double-prime	(207.55)	0.31	98.3	705	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	not computable	(3.61x)				
interest expense must exceed $100,000						
Current ratio	0.49x	2.68x	96.2	781	2025-12-31	
Growth and financing, sleeve percentile 89.4						
Revenue growth, three-year compound	(2.4%)	9.6%	77.2	400	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	(43.2%)	3.2%	98.2	663	2025-12-31	
Net share issuance, one year	371.1%	1.6%	92.9	625	2026-03-20	

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 371.1%
Short runway	cash runway is 2.0 months
Thin data	6 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(97.2%)	(1.7%)	0
Distance from 52-week high	(98.3%)	(31.7%)	1
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(860.8%)	0.6%	1
Book value to price	0.57	0.29	72
Sales to price	2.11	0.37	88
Composite equity issuance, five years	372.8%	13.5%	97
Relative strength against the sector, log excess return	(3.74)	(0.19)	0
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$5.0M
Operating cash flow, four quarters	-$30.8M
Months of runway	2.0
Days since last periodic filing	7 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$170,133

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$7.6M	2025-12-31	2026-03-24	10-K	26-000043
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.2M	2025-12-31	2026-03-24	10-K	26-000043
3	assets	us-gaap:Assets	$20.0M	2025-12-31	2026-03-24	10-K	26-000043
4	assets	us-gaap:Assets	$41.3M	2024-12-31	2026-03-24	10-K	26-000043
5	current assets	us-gaap:AssetsCurrent	$6.9M	2025-12-31	2026-03-24	10-K	26-000043
6	current liabilities	us-gaap:LiabilitiesCurrent	$14.1M	2025-12-31	2026-03-24	10-K	26-000043
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-24	10-K	26-000043
8	operating income	us-gaap:OperatingIncomeLoss	-$5.7M	2025-12-31	2026-03-24	10-K	26-000043
9	book equity	us-gaap:StockholdersEquity	$5.5M	2025-12-31	2026-03-24	10-K	26-000043
10	liabilities	us-gaap:Liabilities	$14.5M	2025-12-31	2026-03-24	10-K	26-000043
11	operating income	us-gaap:OperatingIncomeLoss	-$42.1M	2021-12-31	2023-03-13	10-K	23-000023
12	interest expense	us-gaap:InterestExpense	$0	2021-12-31	2022-02-24	10-K	22-000002
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.4M	2025-12-31	2026-03-24	10-K	26-000043
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.9M	2024-12-31	2026-03-24	10-K	26-000043
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.0M	2023-12-31	2025-03-31	10-K	25-000031
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.2M	2022-12-31	2024-02-08	10-K	24-000010
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.4M	2023-12-31	2025-03-31	10-K	25-000031
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2024-02-08	10-K	24-000010
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$54.3M	2022-12-31	2024-02-08	10-K	24-000010
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$416,000	2022-12-31	2024-02-08	10-K	24-000010
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$37.6M	2021-12-31	2023-03-13	10-K	23-000023
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2021-12-31	2023-03-13	10-K	23-000023
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$25.7M	2020-12-31	2022-02-24	10-K	22-000002
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$677,000	2020-12-31	2022-02-24	10-K	22-000002
25	assets	us-gaap:Assets	$77.3M	2023-12-31	2025-03-31	10-K	25-000031
26	assets	us-gaap:Assets	$108.8M	2022-12-31	2024-02-08	10-K	24-000010
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	39,978,693	2026-03-20	2026-03-24	10-K	26-000043
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,487,818	2025-03-27	2025-03-31	10-K	25-000031

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.